Literature DB >> 12670552

Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder.

Kao-Peng Guan1, Hai-Yun Ye, Zheng Yan, Ying Wang, Shu-Kun Hou.   

Abstract

OBJECTIVES: To analyze the preoperative serum levels of endostatin and matrix metalloproteinase-9 (MMP-9) in patients with primary transitional cell carcinoma of the bladder according to tumor stage and grade and to evaluate their clinical diagnostic application.
METHODS: Preoperative serum levels of endostatin and MMP-9 were determined in 52 patients with transitional cell carcinoma of the bladder (13 with superficial carcinoma and 39 with advanced carcinoma) and 32 healthy controls by enzyme-linked immunosorbent assay.
RESULTS: The serum levels of endostatin and MMP-9 were significantly greater in the 52 patients with bladder cancer than in the healthy controls (endostatin 46.8 ng/mL versus 30.6 ng/mL, P <0.001; MMP-9 786 ng/mL versus 417 ng/mL, P <0.001). The endostatin level correlated positively with the MMP-9 level (R = 0.55, P <0.01). Furthermore, the levels of endostatin and MMP-9 were associated with the tumor stage and grade. Patients with distant metastasis (n = 7) had significantly greater levels of endostatin and MMP-9 than patients without metastasis (n = 45) (endostatin 69.8 ng/mL versus 43.3 ng/mL, P <0.001; MMP-9 1529 ng/mL versus 674 ng/mL, P <0.001).
CONCLUSIONS: Elevated endostatin and MMP-9 levels are associated with a greater stage and grade of primary transitional cell carcinoma of the bladder.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12670552     DOI: 10.1016/s0090-4295(02)02429-9

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  16 in total

Review 1.  Biomolecular predictors of urothelial cancer behavior and treatment outcomes.

Authors:  Michael Rink; Eugene K Cha; David Green; Jens Hansen; Brian D Robinson; Yair Lotan; Arthur I Sagalowsky; Felix K Chun; Pierre I Karakiewicz; Margit Fisch; Douglas S Scherr; Shahrokh F Shariat
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

2.  Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with pituitary adenomas.

Authors:  Anna Gruszka; Jolanta Kunert-Radek; Marek Pawlikowski; Henryk Stepien
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 3.  Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengers.

Authors:  Chiara Poluzzi; Renato V Iozzo; Liliana Schaefer
Journal:  Adv Drug Deliv Rev       Date:  2015-10-27       Impact factor: 15.470

Review 4.  Matrix metalloproteinases and their clinical relevance in urinary bladder cancer.

Authors:  Tibor Szarvas; Frank vom Dorp; Süleyman Ergün; Herbert Rübben
Journal:  Nat Rev Urol       Date:  2011-04-12       Impact factor: 14.432

5.  Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole.

Authors:  Emilio Alba; Antonio Llombart; Nuria Ribelles; Manuel Ramos; Roberto Fernández; José Ignacio Mayordomo; Ignasi Tusquets; Miguel Gil; Agustí Barnadas; Francisco Carabante; Manuel Ruiz; Ruth Vera; Isabel Palomero; Vicente Soriano; Jesús González; Ramón Colomer
Journal:  Clin Transl Oncol       Date:  2006-03       Impact factor: 3.405

6.  Fluorescence detection of MMP-9. I. MMP-9 selectively cleaves Lys-Gly-Pro-Arg-Ser-Leu-Ser-Gly-Lys peptide.

Authors:  Rafal Fudala; Amalendu P Ranjan; Anindita Mukerjee; Jamboor K Vishwanatha; Zygmunt Gryczynski; Julian Borejdo; Pabak Sarkar; Ignacy Gryczynski
Journal:  Curr Pharm Biotechnol       Date:  2011-05       Impact factor: 2.837

7.  Effects of endostatin on expression of vascular endothelial growth factor and its receptors and neovascularization in colonic carcinoma implanted in nude mice.

Authors:  Yun-He Jia; Xin-Shu Dong; Xi-Shan Wang
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

8.  Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species.

Authors:  Roopali Roy; Gwendolyn Louis; Kevin R Loughlin; Dmitri Wiederschain; Susan M Kilroy; Carolyn C Lamb; David Zurakowski; Marsha A Moses
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

9.  Elevated matrix metalloproteinase-9 expression may contribute to the pathogenesis of bladder cancer.

Authors:  Fan-Chang Zeng; Song Cen; Zheng-Yan Tang; Xin-Li Kang
Journal:  Oncol Lett       Date:  2016-02-04       Impact factor: 2.967

10.  Antisense MMP-9 RNA inhibits malignant glioma cell growth in vitro and in vivo.

Authors:  Cuiyun Sun; Qian Wang; Hongxu Zhou; Shizhu Yu; Alain R Simard; Chunsheng Kang; Yanyan Li; Yanling Kong; Tongling An; Yanjun Wen; Fudong Shi; Junwei Hao
Journal:  Neurosci Bull       Date:  2013-01-10       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.